This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Humana (HUM) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 20.10% and 2.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Humana (HUM)
by Zacks Equity Research
Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Watch These 5 Medical Stocks for Q1 Earnings: Beat or Miss?
by Debasmita Chatterjee
Improved premiums resulting from membership growth, and higher patient admissions are expected to have driven the Q1 performance of HUM, MOH, UHS, EHC and CYH. An elevated operating expense level is likely to have dented growth prospects.
Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?
by Zacks Equity Research
Humana's (HUM) first-quarter results are likely to reflect rising premiums and investment income.
Analysts Estimate Centene (CNC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Analyst Projections for Key Metrics Reveal About Humana (HUM) Q1 Earnings
by Zacks Equity Research
Evaluate the expected performance of Humana (HUM) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Humana (HUM) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $324.83, moving +0.42% from the previous trading session.
Humana (HUM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brokers Suggest Investing in Humana (HUM): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Humana (HUM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Humana (HUM) Stock Moves -1.17%: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $312.59, marking a -1.17% move from the previous day.
Centene (CNC) Wins Medicaid Contract to Better Serve Michigan
by Zacks Equity Research
Centene's (CNC) Meridian secures a contract from the Michigan Department of Health and Human Services, which gives it the opportunity to better serve the health needs of the state's Medicaid members.
CI vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?
Humana's (HUM) Medicaid Business Teams Up With CPESN USA in Ohio
by Zacks Equity Research
Humana's (HUM) partnership with CPESN USA in Ohio aims to overcome barriers like limited access to healthcare services in rural and underserved communities.
Pre-Markets in Red Before Key Economic Data
by Zacks Equity Research
Pre-Markets in Red Before Key Economic Data.
Pre-Market Futures Lower Ahead of JOLTS, U.S. Auto Sales
by Mark Vickery
Markets look to start a new trading day in the red after closing lower Monday. Bond yields, gold and oil are all up.
Health Insurance Stocks Drop: Insights Into the Late Monday Fall
by Kaibalya Pravo Dey
Higher costs and lower hikes in rates can lead to lower profit growth, which concerns investors.
Humana (HUM) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Humana (HUM) concluded the recent trading session at $351.45, signifying a +1.36% move from its prior day's close.
Is It Worth Investing in Humana (HUM) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Humana (HUM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Humana (HUM) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $347.09, moving -0.42% from the previous trading session.
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
by Zacks Equity Research
Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.
Humana (HUM) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Humana (HUM) concluded the recent trading session at $347.19, signifying a -0.28% move from its prior day's close.
CI or HUM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?
Are These 3 Beaten-Down S&P 500 Members Worth a Look?
by Derek Lewis
The market has enjoyed a fantastic run in 2024, building nicely on last year???s gains. But not all have joined the party, specifically these three. Deep in the red year-to-date, are they worth a look?